Oakworth Capital Inc. Cuts Stock Position in Pfizer Inc. (NYSE:PFE)

Oakworth Capital Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 20.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 60,532 shares of the biopharmaceutical company’s stock after selling 16,010 shares during the period. Oakworth Capital Inc.’s holdings in Pfizer were worth $1,743,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Front Street Capital Management Inc. grew its position in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 215 shares during the last quarter. Castleview Partners LLC grew its position in Pfizer by 2.4% during the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 287 shares during the last quarter. United Bank grew its position in Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares during the last quarter. Compton Capital Management Inc. RI grew its position in Pfizer by 0.5% during the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock worth $3,308,000 after purchasing an additional 300 shares during the last quarter. Finally, GHP Investment Advisors Inc. grew its position in Pfizer by 2.4% during the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 307 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.9 %

Shares of NYSE:PFE traded down $0.23 during trading on Wednesday, hitting $25.46. 35,014,684 shares of the company were exchanged, compared to its average volume of 42,444,172. The firm’s 50 day moving average price is $27.23 and its 200-day moving average price is $28.79. The stock has a market capitalization of $144.17 billion, a P/E ratio of 71.36, a PEG ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a 12-month low of $25.26 and a 12-month high of $41.33. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 EPS. On average, research analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on PFE shares. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.